This content is machine translated Moderate to severe chronic hand eczema Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland In the phase III DELTA 1 and 2 studies, delgocitinib cream showed a rapid onset of efficacy – at week 16, half of the patients achieved a 75% improvement in...…
View Post 4 min This content is machine translated Oral JAK-i in atopic dermatitis Benefits and risks: What does the current data say? Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of...…
View Post 6 min This content is machine translated Chronic hand eczema Changing therapy landscape – a lot is happening Inflamed, itchy and sometimes painful skin lesions on the hands can significantly impair quality of life. If chronic hand eczema proves to be refractory to topical treatment, systemic therapy is...…
View Post 5 min This content is machine translated Rheumatoid arthritis JAK inhibitor reduces pain for a long time Patients with active rheumatoid arthritis often suffer from considerable pain. Therefore, pain control is an important treatment goal in this patient group. In a post-hoc analysis of the FINCH studies…
View Post 11 min This content is machine translated Therapy of rheumatoid arthritis Long-term safety for RA patients under JAK inhibition The treatment of rheumatoid arthritis (RA) has made great progress over the past 20 years. This relates both to the range of drugs available and to developments in terms of… CME-Test
View Post 4 min This content is machine translated Atopic dermatitis Long-term efficacy of baricitinib proven In adult patients with moderate to severe atopic dermatitis, long-term therapy with the JAK inhibitor baricitinib maintained improvements achieved after 16 weeks for 68 weeks, new data show. A pooled…
